C.COOL $COOL (Core One Labs) - biotechnology research and development enterprise $COOL just announced their share purchase agreement with Akome Biotech. Core ONE LABS will obtain all of Akome’s outstanding share capital.
This “definitive agreement” is really fuelling $COOL ’s fire in advancing psychedelic medicine to management markets of stroke, depression, Alzheimer’s, and Parkinson’s disease.
Core one labs CEO shares:
“This acquisition will put us at the forefront of research into the use of psychedelics for treatment across multiple diseases, elevating our company’s portfolio to be comparable with the largest company in the space.”
check out full article :
https://ceo.ca/@nasdaq/repeat-core-one-labs-reaches-definitive-agreement
$COOL closed at $0.89, down 6.3% on more than double avg volume
market cap $63.16 M